{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:17:04Z","timestamp":1793733424751,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2018SK2124"],"award-info":[{"award-number":["2018SK2124"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2018SSK2120"],"award-info":[{"award-number":["2018SSK2120"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2019JJ50360"],"award-info":[{"award-number":["2019JJ50360"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2019SK2032"],"award-info":[{"award-number":["2019SK2032"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["NCT05206656"],"award-info":[{"award-number":["NCT05206656"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["YYS-20200305"],"award-info":[{"award-number":["YYS-20200305"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2023JJ60464"],"award-info":[{"award-number":["2023JJ60464"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010451","name":"Health and Family Planning Commission of Hunan Province","doi-asserted-by":"publisher","award":["B2019089"],"award-info":[{"award-number":["B2019089"]}],"id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010451","name":"Health and Family Planning Commission of Hunan Province","doi-asserted-by":"publisher","award":["C2019070"],"award-info":[{"award-number":["C2019070"]}],"id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011496","name":"Changsha Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019054","name":"Changsha Science and Technology Project","doi-asserted-by":"publisher","award":["CORP-239-S5"],"award-info":[{"award-number":["CORP-239-S5"]}],"id":[{"id":"10.13039\/501100019054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019054","name":"Changsha Science and Technology Project","doi-asserted-by":"publisher","award":["kq1901076"],"award-info":[{"award-number":["kq1901076"]}],"id":[{"id":"10.13039\/501100019054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019054","name":"Changsha Science and Technology Project","doi-asserted-by":"publisher","award":["kq2004125"],"award-info":[{"award-number":["kq2004125"]}],"id":[{"id":"10.13039\/501100019054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019054","name":"Changsha Science and Technology Project","doi-asserted-by":"publisher","award":["kq2004137"],"award-info":[{"award-number":["kq2004137"]}],"id":[{"id":"10.13039\/501100019054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.esmoop.2023.101563","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:16:58Z","timestamp":1686129418000},"page":"101563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"B.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.-Y.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.101563_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2023.101563_bib2","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/cam4.4652","article-title":"Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101563_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.20892\/j.issn.2095-3941.2020.0463","article-title":"Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer","volume":"18","author":"Hu","year":"2021","journal-title":"Cancer Biol Med"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101563_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.esmoop.2023.101563_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101563_bib6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9769","key":"10.1016\/j.esmoop.2023.101563_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101563_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncponc0905","article-title":"Mechanisms of disease: angiogenesis and the management of breast cancer","volume":"4","author":"Banerjee","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101563_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2023.101563_bib10","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101563_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.breast.2020.09.011","article-title":"First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: efficacy and safety in the GINECO phase II ESMERALDA study","volume":"54","author":"Hardy-Bessard","year":"2020","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101563_bib12","article-title":"Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)","volume":"6","author":"De Angelis","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101563_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211030210","article-title":"Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study","volume":"13","author":"Zhao","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2023.101563_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101563_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101563_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/ol.2021.13164","article-title":"Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C","volume":"23","author":"Fang","year":"2022","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101563_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.31083\/j.fbl2704125","article-title":"Anti-cancer drug anlotinib promotes autophagy and apoptosis in breast cancer","volume":"27","author":"Chen","year":"2022","journal-title":"Front Biosci"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101563_bib18","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1097\/CAD.0000000000001171","article-title":"Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report","volume":"33","author":"Zheng","year":"2022","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101563_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101563_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.breast.2022.07.010","article-title":"The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: novel prognostic indexes based on ctDNA","volume":"65","author":"Liu","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2023.101563_bib21","article-title":"Co-expression and combined prognostic value of CSPG4 and PDL1 in TP53-aberrant triple-negative breast cancer","volume":"12","author":"Hu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.101563_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ebiom.2018.05.015","article-title":"Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance","volume":"32","author":"Hu","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.esmoop.2023.101563_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2022.40.16_suppl.1094","article-title":"Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: results of a phase II study","volume":"40","author":"Liu","year":"2022","journal-title":"Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101563_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clbc.2016.07.005","article-title":"Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, phase II study","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101563_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101563_bib26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101563_bib27","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101563_bib28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-17-1467","article-title":"Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery","volume":"78","author":"Wozniak","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101563_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12640-017-9729-6","article-title":"Microtubule-targeting agents eribulin and paclitaxel differentially affect neuronal cell bodies in chemotherapy-induced peripheral neuropathy","volume":"32","author":"Benbow","year":"2017","journal-title":"Neurotox Res"},{"key":"10.1016\/j.esmoop.2023.101563_bib30","article-title":"The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: a multicenter retrospective study","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2023.101563_bib31","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101563_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10549-019-05400-y","article-title":"Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)","volume":"178","author":"Kim","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101563_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101563_bib34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"Mcgrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101563_bib35","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.3390\/cancers14174084","article-title":"A\u00a0real-world multicentre retrospective study of low-dose apatinib for human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"14","author":"Zeng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.101563_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915305","article-title":"FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients","volume":"12","author":"Xie","year":"2020","journal-title":"Ther Adv Med Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923007937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923007937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:20Z","timestamp":1761856160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923007937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2059702923007937"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101563","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101563"}}